Predictive Biosciences' CertNDx Case Study Published in BMC Urology
10/17/2012 9:36:24 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive Biosciences, an innovative developer of molecular diagnostic tests, announced today that a case study using the CertNDx™ Bladder Cancer Assay was published in BMC Urology by Dr. Daniel M. Silverberg of Urology Specialists of the Lehigh Valley in Allentown, PA. The article entitled “Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report” can be accessed online at BMC Urology. FGFR3 mutations have been shown to exist in up to 50% of cancers found in the urinary bladder and upper urinary tract, but only a handful of research institutions throughout the world have attempted to detect them. With the introduction of the CertNDx Bladder Cancer Assay, a non-invasive molecular diagnostic test, urologists across the United States now have the ability to detect bladder and upper urinary tract cancers using FGFR3 mutation detection in urine. This case demonstrates the CertNDx Bladder Cancer Assay’s ability to detect an upper tract cancer in a real-world medical practice.